Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | JUN | P05412 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320559 | 0.83 | JUN (0.57) | FDPSALDH1A1JUNNFKB1TSHR | |
| SCHEMBL31190039 | 0.83 | JUN (0.57) | FDPSALDH1A1JUNNFKB1TSHR | |
| SCHEMBL30262368 | 0.82 | FDPS (0.71) | FDPSALDH1A1SMN1; SMN2POLBTSHR | |
| SCHEMBL7034558 | 0.82 | FDPS (0.71) | FDPSALDH1A1SMN1; SMN2POLBTSHR | |
| SCHEMBL16294326 | 0.81 | ALDH1A1 (0.55) | FDPSALDH1A1SMN1; SMN2POLBKDM4E | |
| SCHEMBL17039415 | 0.81 | FDPS (0.53) | FDPSALDH1A1SMN1; SMN2POLBJUN | |
| SCHEMBL3138383 | 0.81 | ALDH1A1 (0.61) | FDPSALDH1A1SMN1; SMN2TSHRKDM4E | |
| SCHEMBL975113 | 0.79 | ALDH1A1 (0.69) | FDPSALDH1A1HIF1APOLBJUN | |
| SCHEMBL31009650 | 0.79 | ALDH1A1 (0.66) | FDPSALDH1A1SMN1; SMN2POLBTSHR | |
| SCHEMBL1121580 | 0.79 | ALDH1A1 (0.66) | FDPSALDH1A1SMN1; SMN2POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-7314888-B1 | Compounds and medicinal use thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| EP-1127869-A1 | NOVEL COMPOUNDS AND MEDICINAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | SP1, AP1G1, AP1M1 | FDPS 3155/4885ALDH1A1 2031/4885SMN1; SMN2 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.